Funding from Foundations/Private Sources

Funding for Prostate Cancer Research

DEADLINE: Monday, January 4, 2010

Funding is available to support multidisciplinary research in prostate cancer through the
Patrick C. Walsh Prostate Cancer Research Fund. Awards of a maximum of $75,000 per year for up to two years are available to fund career development and developmental research programs (pilot projects).

New Ideas Encouraged!

For more information, visit the website @: http://prostatecancerprogram.onc.jhmi.edu/

Department of Defense (DOD) Lung Cancer Research Program
The FY09 Lung Cancer Research Program has released the Program Announcement/Funding Opportunity for the Lung Cancer Biospecimen Resource Network (LCBRN) Award. The LCBRN award is intended to provide infrastructure support for the development of a lung cancer biospecimen resource that will facilitate the collection, processing, annotation, storage, and distribution of high-quality human lung cancer biospecimens through a collaborative network across multiple institutions. The LCBRN will consist of a Coordinating Center that will also function as a biospecimen resource site and a minimum of two additional Biospecimen Resource Sites that will be jointly responsible for developing the biospecimen resource network for lung cancer research.

The Coordinating Center and Biospecimen Resource Sites must submit a single application.

The proposed LCBRN must collect, process, annotate, store, and distribute human lung cancer biospecimens that support two or more of the Areas of Emphasis listed below:

• Identification or development of non-invasive or minimally invasive tools to improve the detection of the initial stages of lung cancer.
  
• Identification and development of tools for screening or early detection of lung cancer. Screening may include, but is not limited to, computed tomography scans, X-rays, other imaging, biomarkers, genetics/genomics/proteomics, and assessment of risk factors.
  
• Understanding the molecular mechanisms that lead to clinically significant lung cancer.
  
• Identification of the mechanisms that lead to the development of the various types of lung cancer.
  
• Identification of innovative strategies for prevention and treatment of early lung cancer.
  
• Understanding predictive and prognostic markers to identify responders and non-responders.
  
• Understanding acquired resistance to treatment.

Submission is a two-step process consisting of pre-application submission and application submission. Pre-applications are REQUIRED for all award mechanisms.

Complete details about this opportunity may be found on the Congressionally Directed Medical Research Programs website at http://cdmrp.army.mil/funding/lcrp.htm
or on grants.gov at http://www07.grants.gov/search/search.do?&mode=
VIEW&flag2006=false&oppId=49421

DEADLINES:

• Pre-Application (Pre-proposal) through http://cdmrp.org required and due: December 23, 2009; 5:00 p.m. Eastern Time.
  
• Application submitted through http://www.grants.gov due January 6, 2010; 11:59 p.m. Eastern Time.
  

Funding Opportunity for Combat-Relevant Orthopaedic Research Clinical Consortium

Fiscal Year 2009 (FY09) congressional appropriations have provided $112 million to the Department of Defense DOD) Peer Reviewed Orthopaedic Research Program (PRORP). This program will support innovative, high-impact, clinically relevant research to advance treatment and rapid rehabilitation from musculoskeletal injuries sustained during military combat or combat-related activities.

The PRORP Clinical Consortium Award is being offered for the first time in FY09. The intent of the award is to fund clinical studies focused on improving the outcomes of severe musculoskeletal injuries commonly associated with military combat. The main objective of this Consortium Award is to address questions that need to be answered through large multi-site clinical trials with appropriate statistical power. The award is designed to combine the population of military orthopaedic trauma patients and the combat-relevant expertise of PRORP-specified military treatment facilities with the patient populations and research expertise of highly qualified civilian orthopaedic trauma departments at outstanding institutions. Clinical outcomes will require longitudinal evaluations of definitive care which should include surgical reconstruction, clinical rehabilitation, and return to optimal function. The expected end results are an established infrastructure for continuing clinical studies on combat-relevant musculoskeletal injuries, and products (information, guidelines, validated techniques, or devices) that result in changes to, or validation of, current clinical practice that lead to better outcomes for our injured warriors. Pre-applications are REQUIRED for all PRORP award mechanisms.

Pre-Application (Letter of Intent) Deadline: December 23, 2009
Application Deadline: January 11, 2010
Funding Opportunity Number: W81XWH-09-PRORP-CCA

A detailed description of the award mechanism can be found in the FY09 PRORP Program Announcement and Application Instructions & General Information documents, which are available from the Grants.gov website (http://www.grants.gov), the CDMRP website (http://cdmrp.army.mil/funding/prorp.htm) and the CDMRP eReceipt Website (https://cdmrp.org).

Maryland Stem Cell Commission Issues Requests for Applications

The Maryland Stem Cell Commission has issued three official Requests for Applications (RFAs) for funding through the Maryland Stem Cell Research Fund under the Maryland Stem Cell Research Act. The grants to be awarded under these three RFAs will fund basic and translational research with human stem cells of all types, as defined in the Stem Cell Act. The goals of this program are to broaden and advance knowledge of human stem cell biology that will be relevant for eventual development of clinical applications, and to enable, support and accelerate such clinical applications for prevention, diagnosis and treatment of human diseases and conditions.

A one-page Letter of Intent is required and must be submitted by Nov. 12, 2009. Applications for funding under these RFAs will be due Jan. 14, 2010.

RFA-MD-10-1 is soliciting applications for Investigator-Initiated Research Grants, which are designed for investigators with preliminary data supporting the grant application. These Investor-Initiated Research Grants will be for up to $1 million of direct costs over a two-to-five year project.

RFA-MD-10-2 is soliciting applications for Exploratory Research Grants, which are designed for investigators who are new to the stem cell field (young investigators and investigators from other fields), and for new hypotheses, approaches, mechanisms or models that may differ from current thinking in the stem cell field, without any preliminary data supporting the application. These Exploratory Research Grants will be for up to $100,000 of direct costs per year, for up to two years.

RFA-MD-10-3 is soliciting nationwide applications for post-doctoral fellows who wish to conduct research on all types of human stem cells in Maryland. Each fellowship being awarded is up to $55,000 per year for up to two years, which is inclusive of all direct, indirect and fringe benefits costs.

The Commission will give the highest priority to scientifically meritorious applications that include collaboration between for-profit and not-for-profit organizations in the state.

The work funded under these RFAs must be conducted in Maryland. The scientists and clinicians conducting the work must be employed or retained by an eligible Maryland-based organization while doing so.

All applications must include an explanation of the translation potential, a plan of the proposed research as well as a bioethics section. All Principal Investigators funded under these RFAs will be required to present their interim and final research results at an annual in-state symposium and in annual reports to the Maryland Stem Cell Research Commission.

New cell lines initially developed with funding under these RFAs will be required to be shared with other qualified researchers.

Key Dates:

• Letter of Intent Receipt Deadline: Nov. 12, 2009
• Application Receipt Deadline: Jan. 14, 2010
• Peer Review: March 2010
• Commission Decision: April 2010
• Earliest Anticipated Start: June 2010

For more details on each of these funding opportunities, click here: http://www.mscrf.org/content/fundingopps/index.cfm

Questions about these RFAs may only be addressed via the following contact: mscrfinfo@MarylandTEDCO.org.

Return to top of Funding Opportunities